Business · 02/07/2025Updated: 10/17/2026 · 1 min read
FDA Corrects Notice on Patent Extension for ELREXFIO
Summary
The FDA is correcting a notice that incorrectly listed only one of two docket numbers for the patent extension of ELREXFIO (elranatamab-bcmm), a treatment for certain cancers, as published in the Federal Register on May 12, 2025.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →